Readmissions for CRS, neurotoxicity, infection, and other adverse events are common after immunotherapy with axicabtagene ciloleucel.
Structured palliative care can ensure these patients and their caregivers have an optimal experience that does not hinder trial outcomes.
Estimated 785 fewer cancer deaths in 2017 in states that expanded Medicaid.
A patient education and monitoring program improved patients’ ability to manage and report adverse events related to treatment with ICIs.
Progression-free and overall survival were worse among patients with HLH receiving CAR-T cell therapy by 10-month follow-up.
Obinutuzumab plus chemotherapy showed more durable efficacy, safety, and longer progression-free survival for patients with untreated follicular lymphoma.
Promising follow-up data on safety and efficacy of fixed-duration venetoclax-obinutuzumab for patients with untreated CLL.
Only 2 patients received hydroxychloroquine as part of a clinical trial, and about 10% were taking the drug at the time of their COVID-19 presentation.
Carfilzomib plus lenalidomide and dexamethasone failed to improve outcomes compared with bortezomib plus lenalidomide and dexamethasone among patients with newly-diagnosed MM.
Patients undergoing allogeneic stem cell transplantation who experience C difficile infections may have an increased risk for graft vs host disease.
Using data from 108 patients, researchers designed MIPI-P, a novel scoring system for determining MCL prognosis.
Physicians noted that patients receiving best supportive care were more likely to be interested in low-intensity treatments if the risk for side effects was lower.
This phase 2 study used a crossover design in which study medication and placebo were administered to all patients in cycles A and B of chemotherapy, respectively.
No systematic investigations have evaluated the publication timing of oncology drug registration trial results relative to the approval of these drugs by the FDA.
Researchers aimed to determine whether the addition of radiotherapy was associated with a risk for adverse events among patients treated with ICIs.
All 5 patients had a complete response or complete response with incomplete hematologic recovery, and 4 of the 5 patients were minimal residual disease–negative.
Despite survival improvements in refractory anemia compared with other subtypes of MDS, patients may still have an increased risk for secondary AML.
Core limitations were defined as lack of randomization, lack of overall survival data, inappropriate use of crossover, and use of suboptimal control arms.
The data reinforce the need for direct comparison of CAR-T and autologous transplantation.
Zanubrutinib demonstrated statistically significant and clinically meaningful advantages in safety and tolerability in patients with WM compared with ibrutinib.